FoundationOne® Heme is a fully informative Comprehensive Genomic Profile from Foundation Medicine, Inc. for hematologic cancers (leukemia, lymphoma and myeloma) and sarcomas. FoundationOne® Heme is designed to provide physicians with clinically actionable information to guide treatment options for patients based on the genomic profile of their cancer. Results are provided in a user-friendly interpretive report. FoundationOne® Heme uses proprietary next-generation sequencing techniques to assess routine cancer specimens for all genes that are known to be somatically altered in hematologic malignancies and sarcomas. It is Foundation Medicine's second commercially available genomic profiling solution.
Roche is collaborating with Foundation Medicine, Inc. to commercialize FoundationOne® Heme in countries outside of the United States.